

## פטנט פצעי סכרת

זהו פרויקט מדהים שסחף את אורי תוכנה לתחום הביוטכנולוגיה.

הפרויקט זכה להצלחה רבה בריפוי פצעי סכרת (כ 90%).

החשוב ביותר הוא שהריפוי עצמו מתבסס כל כולו על מוצרים טבעיים



## הכרת המושגים:

המחלה מתאפיינת ב-3 צורות עיקריות של סוכרת: מסוג 1 ("סוכרת נעורים"), סוכרת מסוג 2, וסוכרת היריון שיש להן תסמינים והשלכות דומות, אבל הן בעלות סיבות שונות והתפלגויות שונות באוכלוסייה.

כל צורות הסוכרת נגרמות בגלל בעיה כלשהי בייצור אינסולין או בקליטתו:

בסוכרת מסוג 2 הגוף במצב שבו תאי בטא והלב לב אינם מסוגלים לייצר כמות מספקת של אינסולין, או במצב שבו מיוצר אינסולין, אף ברמה גבוהה מהדרוש, אבל הגוף מפתח תנגודת להשפעותיו.

## הכרת המושגים:

**סכרת** - הפרעה בחילוף החומרים בגוף, הגורמת לעלייה ברמות הסוכר (גלוקוז) בדם ובשתן.



**פצע** - פצעים שאינם מתרפאים הם אחד מהסיבוכים הקשים של מחלת הסכרת. פצע כרוני הוא סיבוך נלווה לבעיות חסימות כלי דם שמאפיינות.



**נמק** - פצע אשר אינו מתרפא כתוצאה מחוסר הספקת דם מספקת. רמות סוכר גבוהות גורמות שינוי בדפוסי זרימת הדם ומבנה כלי הדם ועלולות לגרום, בין היתר, לנמק.



**כריתה** - סכרת היא הסיבה מספר אחת לכריתת רגל בעולם המערבי. ברגל סוכרתית מחזור הדם לעתים אינו טוב, העור יבש, ועלול להיות מצופה בקשקשים. הסיכון הוא להיווצרות פצע או כיב שאינו מחלים.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 March 2009 (12.03.2009)

PCT

(10) International Publication Number  
**WO 2009/031153 A2**

(51) International Patent Classification: **Not classified**

(21) International Application Number:  
PCT/IL2008/001203

(22) International Filing Date:  
7 September 2008 (07.09.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
185775 6 September 2007 (06.09.2007) IL

(71) Applicant (for all designated States except US): **ORI SOFTWARE** [IL/IL]; P.O.Box 677, 37/29 Yafe Nof Street, 78792 Ashkelon (IL).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KLEIN, Mordechai** [IL/IL]; 8 Hagai Street, 52246 Ramat Gan (IL).

(74) Agents: **LUZZATTO & LUZZATTO** et al.; P.O.Box 5352, 84152 Beer Sheva (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

מס' PCT: 2009/031153 WO

תאריך הגשה: 12.03.2009 לא ננטש

הפטנט הוגש ב... : ארה"ב, הודו וישראל

PCT על שם: אורי תוכנה

## What we have:

- Unique natural botanical formulation for diabetes sores treatment.
- Highly effective solution for the problematic of diabetes sores.
- Experian and years of developing brings Logic INC to have a product and a method to treat diabetes sores.

## Project goal

**Modified herbal mixtures for  
diabetes sores treatment**

**Pictures:**



## תמונות מהמפגשים - חולי סכרת:



# APPENDIX D

## Alf Fischbein, MD

### Bio-sketch

**Alf Fischbein, MD** is an international authority in *Occupational and Environmental Health* with long experience and expertise in areas such as metal toxicology, immunotoxicology, occupational lung diseases, reproductive toxicology, biomarkers of exposures and cancer associated with occupational and environmental exposures.

A graduate of the Faculty of Medicine of the University of Lund, Sweden, he subsequently was an Associate Professor and senior faculty member for two decades at the Mount Sinai School of Medicine of the City University of New York in its Division of Environmental and Occupational Medicine. He has been Visiting Professor at Sackler School of Medicine, Tel Aviv University.

He has pioneered the development and application of *innovative diagnostic devices* in metal toxicology, particularly lead poisoning. He has been part of a team that developed protocols for *clinical trials of pharmaceuticals*, including immunomodulators, which have gained US FDA approval. He is currently active in the field of *biotechnology and regenerative medicine*, and collaborates with an international network of medical scientists in Sweden, USA and Japan, as co-developer of *various innovative therapeutic agents, bio-adhesives and diagnostic devices*. Other areas of expertise and interest include *alternative energy sources, energy conservation and resource recovery* as part of projects in *clean-tech and green-tech*.

Dr. Fischbein is a *liaison to international venture capital entities specializing in developing the global potential and value of biotechnology business*, as well as to leading experts in *long-term strategic business development*. He is an *International Affiliate of Katan Associates International*, Hermosa Beach, California and *is in close collaboration with Big Ben Venture, Detroit, Michigan*. His international renown is reflected in his serving on expert committees of *the International Labour Office in Geneva, Switzerland, the US Environmental Protection Agency and The International Federation of Metalworkers, Geneva, Switzerland*. Dr. Fischbein is a *former Assistant Editor of the American Journal of Industrial Medicine*. Publications include over 160 research publications and several book chapters in leading textbooks of *Environmental and Occupational Medicine*.

## Summary

### **Development of Innovative Treatment of Psoriasis – Possible Breakthrough towards a Cure -**

The project concerns the development of an innovative product aimed as a treatment for psoriasis with likely effect against various forms of the disease. The product consists of a botanical complex, obtained by an innovative technology for the extraction of biologically active substances (BAS) from plants. The components of the extract are categorized as GRAS (Generally Regarded as Safe). Current research includes modification of the herbal complex by a nano-technological process in conjunction with an innovative transdermal drug delivery system.

Preliminary clinical testing among 90 patients by topical application, in a non-clinical trial setting, points towards a remarkable effect of a prototype formulation. Although typical time course for normalization or near normalization of skin was 8-16 weeks, *significant effect was noticed after 6 -15 applications (twice daily), i.e. during the first week. In general, there was no re-occurrence of disease in treated areas subsequent to discontinuation of treatment.* Clinical benefit was also observed in untreated lesions that were located adjacent to a treated area. Long-term surveillance of treatment results reaches about 2 years.

A research and development plan is aimed at obtaining additional refined data regarding the detailed composition of the extract. For that purpose collaboration has been established with the R&D department of a leading, certified company in Europe that processes plant extract and which is a supplier to the pharmaceutical and cosmetics industries in several countries.

Toxicity and efficacy will be studied in great detail in experimental systems utilizing cells of human origin. The mechanism of action against abnormal immunological parameters, which are characteristic for the disease, will be conducted. The initial, remarkable clinical observations will be examined in greater detail in clinical trials. Both of these investigations will be performed in the laboratories and clinical units of dermatology departments in medical centers of international renown.

Successful completion of the development plan would make a partnership with a pharmaceutical company likely. Initial contacts have been established with such a company. The funding is requested in order to reach this important milestone.

**Medical results:**

**מטופל 1**  
**רגל שמאל**  
**מצ"ב תמונות בזמן תחילת הטיפול**

שלב א':

החולה מגיע...





החולה לאחר הטיפול השני...



שלב ג':

החולה לאחר שבוע...





החולה לאחר שבועיים- שלושה...



החולה בסיום הטיפול...



**מטופל 2**  
**רגל שמאל**  
**מצ"ב תמונות בזמן תחילת הטיפול**

שלב א':

החולה מגיע...







## סיום הטיפול



**מטופל 2**  
**רגל ימין**  
**מצ"ב תמונות בזמן תחילת הטיפול**



שלב א':

מטופל חדש



## סיום הטיפול

מחיר חדש



מטופל חדש



**מטופל 3**  
**רגל ימין**  
**מצ"ב תמונות בזמן תחילת הטיפול**



שלב א':

מטופל חדש













## סיום הטיפול





**Thank you for listening...**